Compare LSTA & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSTA | COCH |
|---|---|---|
| Founded | 1980 | 1995 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Misc Health and Biotechnology Services | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9M | 49.7M |
| IPO Year | 2000 | N/A |
| Metric | LSTA | COCH |
|---|---|---|
| Price | $3.34 | $0.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $15.00 | $6.00 |
| AVG Volume (30 Days) | 59.2K | ★ 118.3K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,283,868.00 | N/A |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 56.90 | N/A |
| 52 Week Low | $1.81 | $0.36 |
| 52 Week High | $5.07 | $1.89 |
| Indicator | LSTA | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 53.66 |
| Support Level | $3.02 | $0.64 |
| Resistance Level | $3.41 | $0.73 |
| Average True Range (ATR) | 0.13 | 0.04 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 53.85 | 53.10 |
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.